Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van TAR-200 in combinatie met Cetrelimab of TAR-200 alleen versus intravesicale Bacillus Calmette-Guérin (BCG) bij deelnemers met BCG-naïeve niet-spierinvasieve blaaskanker met hoog risico (SunRISe-3)

24 september 2026 bijgewerkt door: Janssen Research & Development, LLC

Een open-label, multicenter, gerandomiseerde fase 3-studie ter evaluatie van de werkzaamheid en veiligheid van TAR-200 in combinatie met alleen cetrelimab of TAR-200 versus intravesicale Bacillus Calmette-Guérin (BCG) bij deelnemers met BCG-naïeve hoogrisico Niet-spierinvasieve blaaskanker

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetrelimab (Group A) and TAR-200 alone (Group C) versus intravesical BCG (Group B).

Studie Overzicht

Toestand

Actief, niet wervend

Conditie

Gedetailleerde beschrijving

Bladder cancer is the tenth most common malignancy worldwide. About 75 percent (%) of bladder cancers are non-muscle invasive at diagnosis with approximately 25% of NMIBC patients have HR, NMIBC. The TAR-200/gemcitabine (JNJ-17000139) product is an intravesical drug delivery system regulated as an investigational drug. The drug constituent consists of gemcitabine and osmotic minitablets. Cetrelimab (JNJ-63723283) is a fully human immunoglobulin G4 (IgG4) kappa monoclonal antibody (mAb) that binds programmed-cell death protein (PD)-1. The mainstay of treatment for HR-NMIBC is transurethral resection of bladder tumor, followed by intravesical treatment with BCG. In this study metronomic dosing of intravesical gemcitabine, delivered via TAR-200, alone or in combination with cetrelimab will be evaluated and compared against intravesical BCG. The study consists of a Screening phase, Treatment phase, and Follow-up phase. The total duration of the study will be up to 5 years and 2 months. Efficacy, Safety, pharmacokinetics (PK), and biomarkers will be assessed at specific time points during the study.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

1135

Fase

  • Fase 3

Uitgebreide toegang

Goedgekeurd te koop aan het publiek. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Buenos Aires, Argentinië, C1199
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentinië, C1417
        • Sociedade Beneficente de Senhoras Hospital Sirio Libanes
      • Córdoba, Argentinië, X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • Córdoba, Argentinië, 5000
        • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
      • Córdoba, Argentinië, X5000KPH
        • Centro Urologico Profesor Bengio
      • Mar del Plata, Argentinië, B7602CBM
        • Hospital Privado de la Comunidad
      • Río Cuarto, Argentinië, 5800
        • Instituto Medico Rio Cuarto
      • Heidelberg, Australië, 3084
        • Austin Health
      • Macquarie University, Australië, 2109
        • Macquarie University Hospital
      • Nedlands, Australië, 6009
        • Hollywood Private Hospital
      • South Brisbane, Australië, 4101
        • Mater Hospital Brisbane
      • Antwerp, België, 2020
        • ZNA Middelheim
      • Bruges, België, 8000
        • AZ Sint-Jan
      • Bruges, België, 8310
        • AZ Sint-Lucas
      • Ghent, België, 9000
        • AZ Maria Middelares
      • Ghent, België, 9000
        • UZ Gent
      • Libramont-Chevigny, België, 6800
        • Centre Hospitalier de l'Ardenne
      • Roeselare, België, 8800
        • AZ Delta
      • Sint-Niklaas, België, 9100
        • Vitaz
      • Wilrijk, België, 2610
        • GZA Ziekenhuizen- Campus St Augustinus
      • Barretos, Brazilië, 14784-400
        • Fundacao Pio XII
      • Bauru, Brazilië, 17033-495
        • NAIC Nair Antunes Instituto do Cancer
      • Campinas, Brazilië, 13083-888
        • Hospital das Clinicas da Universidade Estadual de Campinas UNICAMP
      • Curitiba, Brazilië, 81520-060
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Natal, Brazilië, 59075-740
        • Liga Norte Riograndense Contra O Cancer
      • Porto Alegre, Brazilië, 90050-170
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Presidente Prudente, Brazilië, 19013-050
        • Hospital Regional do Cancer Hospital de Esperanca
      • Salvador, Brazilië, 41253-190
        • IDOR - Regional Bahia
      • Santa Cruz do Sul, Brazilië, 96835-090
        • Hospital Ana Nery Santa Cruz do Sul
      • Santo André, Brazilië, 09060-870
        • CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
      • São Paulo, Brazilië, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brazilië, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • São Paulo, Brazilië, 05652 900
        • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
      • São Paulo, Brazilië, 1321 001
        • Real e Benemerita Associacao Portuguesa de Beneficencia
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • Nova Scotia Health Authority
    • Ontario
      • Hamilton, Ontario, Canada, L8N 4A6
        • St Josephs Healthcare Hamilton
      • Toronto, Ontario, Canada, M5G 1Z5
        • Princess Margaret Cancer Centre University Health Network
    • Quebec
      • Montreal, Quebec, Canada, H2X 3E4
        • CHUM - Centre hospitalier universitaire de Montreal
      • Québec, Quebec, Canada, G1J1Z4
        • CHU de Quebec Universite Laval Hopital de l Enfant Jesus
      • Saint Jerome Quebec, Quebec, Canada, J7Z 2V4
        • Unite de Recherche Clinique du CISSS des Laurentides
      • Beijing, China, 100730
        • Beijing Hospital
      • Beijing, China, 100034
        • Peking University First Hospital
      • Beijing, China, 101100
        • Beijing Luhe Hospital, Capital Medical University
      • Changchun, China, 130499
        • The First Bethune Hospital of Jilin University
      • Changsha, China, 410013
        • Hunan Province Cancer Hospital
      • Chengdu, China, 610044
        • West China Hospital Sichuan University
      • Chongqing, China, 400000
        • Chongqing University Cancer Hospital
      • Deyang, China, 618000
        • People's Hospital of Deyang City
      • Guangzhou, China, 430030
        • Sun Yat Sen University Cancer Center
      • Hangzhou, China, 310000
        • Zhejiang Provincial People's Hospital
      • Hangzhou, China, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Nanjing, China, 210008
        • Nanjing Drum Tower Hospital
      • Ningbo, China, 315010
        • The First Affiliated Hospital of Ningbo University
      • Shanghai, China, 200025
        • Ruijing Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
      • Shanghai, China, 200400
        • Huadong Hospital Affiliated to Fudan University
      • Shenyang, China, 110004
        • Shengjing Hospital Of China Medical University
      • Tianjin, China, 300211
        • The Second Hospital Of Tianjin Medical University
      • Wenzhou, China, 325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan, China, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an, China, 710061
        • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
      • Yantai, China, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, China, 450008
        • Henan Cancer Hospital
      • Cologne, Duitsland, 50968
        • Urologische Partnerschaft Koln UPK
      • Duisburg, Duitsland, 47169
        • Urologicum Duisburg
      • Erlangen, Duitsland, 91054
        • Universitatsklinikum Erlangen
      • Essen, Duitsland, 45147
        • Universitatsklinikum Essen
      • Frankfurt am Main, Duitsland, 60590
        • Universitaetsklinikum Frankfurt
      • Freiburg im Breisgau, Duitsland, 79106
        • Universitaetsklinikum Freiburg
      • Markkleeberg, Duitsland, 04416
        • Matthias Schulze - Germany
      • Mettmann, Duitsland, 40822
        • Urologie Neandertal Praxis Mettmann
      • München, Duitsland, 81675
        • Klinikum rechts der Isar an der Technischen Universitat Munchen
      • Münster, Duitsland, 48149
        • Universitatsklinikum Munster
      • Nuremberg, Duitsland, 90491
        • Medizinisches Versorgungszentrum - Urologie
      • Nuremberg, Duitsland, 90419
        • Klinikum Nurnberg Nord
      • Nürtingen, Duitsland, 72622
        • Studienpraxis Urologie Nurtingen
      • Regensburg, Duitsland, 93053
        • Caritas-Krankenhaus St. Josef
      • Tübingen, Duitsland, 72076
        • Universitat Tubingen
      • Bordeaux, Frankrijk, 33000
        • Polyclinique Bordeaux Nord Acquitaine
      • Clermont-Ferrand, Frankrijk, 63003
        • CHU Gabriel-Montpied
      • Grenoble, Frankrijk, 38043
        • CHU Grenoble
      • Limoges, Frankrijk, 87000
        • Polyclinique de Limoges - Francois Chenieux
      • Lyon, Frankrijk, 69437
        • Hôpital Edouard Herriot
      • Nantes, Frankrijk, 44093
        • CHU de Nantes hotel Dieu
      • Nîmes, Frankrijk, 30029
        • CHU Nimes
      • Orléans, Frankrijk, 45067
        • Centre Hospitalier Regional d'Orleans (CHRO) - Hopital La Source
      • Paris, Frankrijk, 75013
        • Hôpital Universitaire Pitié-Salpêtrière
      • Paris, Frankrijk, 75018
        • APHP - Hopital Bichat - Claude Bernard
      • Paris, Frankrijk, 75960
        • Groupe Hospitalier Diaconesses Croix Saint Simon
      • Paris, Frankrijk, 75015
        • Hopital Europeen Georges-Pompidou
      • Quint-Fonsegrives, Frankrijk, 31130
        • Clinical La Croix Du Sud - Ramsay Santé
      • Rennes, Frankrijk, 35000
        • Chu Rennes Hopital Pontchaillou
      • Strasbourg, Frankrijk, 67200
        • Institut de Cancerologie Strasbourg Europe ICANS
      • Toulouse, Frankrijk, 31059
        • CHU Rangueil
      • Bangalore, Indië, 560027
        • Health Care Global Enterprises pvt Ltd
      • Chandigarh, Indië, 160012
        • Post Graduate Institute of Medical Education And Research PGIMER
      • Gurugram, Indië, 122001
        • Artemis Hospital
      • Kolkata, Indië, 700094
        • Netaji Subhas chandra Bose Cancer Research Institute
      • Mumbai, Indië, 400012
        • Tata Memorial Hospital
      • Pune, Indië, 411040
        • CIMET s Inamdar Multispeciality Hospital
      • Acquaviva delle Fonti, Italië, 70021
        • Generale Regionale F. Miulli
      • Asti, Italië, 14100
        • Ospedale Cardinal Massaia
      • Avellino, Italië, 83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Castelfranco Veneto, Italië, 31033
        • Ospedale San Giacomo Apostolo, Guardia pediatrica territoriale
      • Milan, Italië, 20141
        • Istituto Europeo di Oncologia
      • Milan, Italië, 20132
        • Ospedale San Raffaele di Milano
      • Naples, Italië, 80138
        • Fondazione G Pascale Istituto Nazionale Tumori IRCCS
      • Ravenna, Italië, 48121
        • Ospedale S. Maria Delle Croci
      • Rome, Italië, 00128
        • Istituto Nazionale Tumori Regina Elena
      • Fuji-shi, Japan, 417-8567
        • Fuji City General Hospital
      • Kanazawa, Japan, 920 8641
        • Kanazawa University Hospital
      • Kashihara-shi, Japan, 634-8522
        • Nara Medical University Hospital
      • Kisarazu-shi, Japan, 292-8535
        • Kimitsu Chuo Hospital
      • Kobe, Japan, 650 0047
        • Kobe City Medical Center General Hospital
      • Kumamoto, Japan, 860-0008
        • National Hospital Organization Kumamoto Medical Center
      • Nagano, Japan, 381-8551
        • Nagano Municipal Hospital
      • Nagasaki, Japan, 852-8501
        • Nagasaki University Hospital
      • Nagasaki, Japan, 852-8511
        • JRC Nagasaki Genbaku Hospital
      • Narashino-shi, Japan, 275-8580
        • Saiseikai Narashino Hospital
      • Toon-shi, Japan, 791-0295
        • Ehime University Hospital
      • Toyama, Japan, 930 0194
        • Toyama University Hospital
      • Ube, Japan, 755-8505
        • Yamaguchi University Hospital
      • Yokohama, Japan, 232 0024
        • Yokohama City University Medical Center
      • Mexico City, Mexico, 14308
        • Consultorio Medico dentro del Hospital Angeles Acoxpa
      • Monterrey, Mexico, 64460
        • Hospital Universitario Dr Jose Eleuterio Gonzalez
      • Monterrey, Mexico, 64710
        • Avix Investigacion Clinica S C
      • Mérida, Mexico, 97000
        • Eme Red Hospitalaria
      • San Luis Potosí City, Mexico, 78260
        • Oncologico Potosino
      • Hoofddorp, Nederland, 2134 TM
        • Spaarne Gasthuis
      • Nijmegen, Nederland, 6524 KD
        • Canisius-Wilhelmina Ziekenhuis
      • Nijmegen, Nederland, 6525 GA
        • Radboud Umcn
      • Bialystok, Polen, 15 276
        • Uniwersytecki Szpital Kliniczny w Bialymstoku
      • Bydgoszcz, Polen, 85 048
        • IN VIVO Sp. z o.o
      • Lublin, Polen, 20 708
        • Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
      • Piotrkow Trybunalski, Polen, 97 300
        • Centrum Medyczne
      • Poznan, Polen, 61 731
        • Clinical Research Center sp z o o MEDIC R s k
      • Słupsk, Polen, 76-200
        • Wojewodzki Szpital Specjalistyczny im Janusza Korczaka
      • Warsaw, Polen, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Warsaw, Polen, 02-647
        • Provita Poliklinika
      • Wroclaw, Polen, 50 556
        • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
      • Coimbra, Portugal, 3000-075
        • Ipo Coimbra
      • Lisbon, Portugal, 1769 001
        • Uls Santa Maria - Hosp. Santa Maria
      • Vila Nova de Gaia, Portugal, 4434 502
        • Uls Gaia Espinho
      • A Coruña, Spanje, 15006
        • Hosp Univ A Coruna
      • Algeciras, Spanje, 11207
        • Hosp. Punta de Europa
      • Barcelona, Spanje, 08025
        • Fund. Puigvert
      • Cadiz, Spanje, 11009
        • Hosp. Puerta Del Mar
      • Castellon, Spanje, 12004
        • Hosp. Gral. Univ. de Castellon
      • L'Hospitalet de Llobregat, Spanje, 08907
        • Hosp. Univ. de Bellvitge
      • Lugo, Spanje, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, Spanje, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanje, 28046
        • Hosp. Univ. La Paz
      • Madrid, Spanje, 28027
        • Clinica Univ. de Navarra
      • Málaga, Spanje, 29010
        • Hosp Virgen de La Victoria
      • Santander, Spanje, 39008
        • Hosp. Univ. Marques de Valdecilla
      • Valencia, Spanje, 46010
        • Hosp. Clinico Univ. de Valencia
      • Kaohsiung City, Taiwan, 833
        • Chang Kung Memorial Hospital
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Taichung, Taiwan, 404
        • China Medical University Hospital
      • Taichung, Taiwan, 40705
        • Taichung Veterans General Hospital
      • Taipei, Taiwan, 11217
        • Taipei Veterans General Hospital
      • Taoyuan, Taiwan, 33382
        • Linkou Chang Gung Memorial Hospital
      • Brno, Tsjechië, 65691
        • Fakultni nemocnice u sv. Anny v Brne
      • Hradec Králové, Tsjechië, 500 05
        • Fakultni nemocnice Hradec Kralove
      • Liberec, Tsjechië, 460 01
        • Krajská nemocnice Liberec a.s.
      • Olomouc, Tsjechië, 779 00
        • Fakultni nemocnice Olomouc
      • Prague, Tsjechië, 100 34
        • Fakultni nemocnice Kralovske Vinohrady
      • Prague, Tsjechië, 15006
        • Fakultni nemocnice v Motole
      • Prague, Tsjechië, 140 59
        • Thomayerova nemocnice, Onkologicka klinika
      • Edinburgh, Verenigd Koninkrijk, EH4 2XU
        • Western General Hospital
      • London, Verenigd Koninkrijk, W6 8RF
        • Charing Cross Hospital
      • London, Verenigd Koninkrijk, SW3 6JJ
        • The Royal Marsden NHS Trust
      • London, Verenigd Koninkrijk, EC1A 7BE
        • St Bartholomews Hospital
      • Plymouth, Verenigd Koninkrijk, PL6 8DH
        • Derriford Hospital
      • Scunthorpe, Verenigd Koninkrijk, DN15 7BH
        • Scunthorpe General Hospital
      • Sheffield, Verenigd Koninkrijk, S10 2JF
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • Stevenage, Verenigd Koninkrijk, SG1 4AB
        • Lister Hospital
      • Truro, Verenigd Koninkrijk, TR1 3LJ
        • Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
    • Arizona
      • Scottsdale, Arizona, Verenigde Staten, 85259
        • Mayo Clinic
    • Arkansas
      • Little Rock, Arkansas, Verenigde Staten, 72211
        • Arkansas Urology
    • California
      • Long Beach, California, Verenigde Staten, 90822
        • VA Long Beach Health Care System
      • Los Alamitos, California, Verenigde Staten, 90720
        • Genesis Research, LLC - West Coast Urology
      • Los Angeles, California, Verenigde Staten, 90048
        • Cedars Sinai Medical Center
      • Sacramento, California, Verenigde Staten, 95630
        • UC Davis Comprehensive Cancer Center
      • San Diego, California, Verenigde Staten, 92123
        • Genesis Research
      • Santa Monica, California, Verenigde Staten, 90404
        • Providence Saint Johns Cancer Institute
      • Santa Rosa, California, Verenigde Staten, 95403
        • Providence Medical Foundation
    • Colorado
      • Lakewood, Colorado, Verenigde Staten, 80228
        • Colorado Clinical Research
    • Florida
      • Hialeah, Florida, Verenigde Staten, 33016
        • Urological Research Network
      • Orlando, Florida, Verenigde Staten, 32806
        • Orlando Health Cancer Institute
      • Sarasota, Florida, Verenigde Staten, 34239
        • Sarasota Memorial Hospital
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30303
        • Grady Memorial Hospital
      • Atlanta, Georgia, Verenigde Staten, 30322
        • The Emory Clinic Department of Urology
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern University
      • Lisle, Illinois, Verenigde Staten, 60532
        • Duly Health and Care
      • Quincy, Illinois, Verenigde Staten, 62301
        • Blessing Hospital
    • Indiana
      • Carmel, Indiana, Verenigde Staten, 46032
        • Urology of Indiana
      • Jeffersonville, Indiana, Verenigde Staten, 47130
        • First Urology
    • Kansas
      • Merriam, Kansas, Verenigde Staten, 66204
        • AMR Kansas City Oncology
      • Wichita, Kansas, Verenigde Staten, 67226
        • Wichita Urology Group
    • Maryland
      • Hanover, Maryland, Verenigde Staten, 21076
        • Chesapeake Urology Research Associates
    • Massachusetts
      • Burlington, Massachusetts, Verenigde Staten, 01805
        • Lahey Hospital & Medical Center
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55455
        • University Of Minnesota
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68114
        • The Urology Center, PC
    • New Jersey
      • Camden, New Jersey, Verenigde Staten, 08103
        • Cooper Health System MD Anderson Cancer Center at Cooper
    • New York
      • New York, New York, Verenigde Staten, 10029
        • Icahn School of Medicine at Mt. Sinai
      • New York, New York, Verenigde Staten, 10010
        • VA NY Harbor Healthcare System
      • Syracuse, New York, Verenigde Staten, 13210
        • SUNY Upstate Med Univ
      • Syracuse, New York, Verenigde Staten, 13210
        • Associated Medical Professionals of Ny
    • North Carolina
      • Greenville, North Carolina, Verenigde Staten, 27834
        • Vidant Urology - Greenville
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44195
        • Cleveland Clinic
      • Gahanna, Ohio, Verenigde Staten, 43230
        • Central Ohio Urology Group
    • Pennsylvania
      • Bala-Cynwyd, Pennsylvania, Verenigde Staten, 19004
        • Centers for Advanced Urology LLC d b a MidLantic Urology
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Thomas Jefferson University Hospital
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • UPMC Shadyside Hospital
    • South Carolina
      • Myrtle Beach, South Carolina, Verenigde Staten, 29572
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Vanderbilt University Medical Center
      • Nashville, Tennessee, Verenigde Staten, 37209
        • Urology Associates
    • Texas
      • Austin, Texas, Verenigde Staten, 78745
        • Urology Austin
      • Dallas, Texas, Verenigde Staten, 75231
        • Urology Clinics of North Texas
      • Houston, Texas, Verenigde Staten, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Verenigde Staten, 77027
        • Houston Metro Urology
      • San Antonio, Texas, Verenigde Staten, 78229
        • Urology San Antonio Research
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • Huntsman Cancer Institute
      • Salt Lake City, Utah, Verenigde Staten, 84148
        • George E. Wahlen VAMC
    • Virginia
      • Virginia Beach, Virginia, Verenigde Staten, 23462
        • Urology Of Virginia, Pllc
    • Washington
      • Spokane, Washington, Verenigde Staten, 99202
        • Spokane Urology
      • Busan, Zuid -Korea, 49241
        • Pusan National University Hospital
      • Cheongju-si, Zuid -Korea, 28644
        • Chungbuk National University Hospital
      • Daegu, Zuid -Korea, 41404
        • Kyungpook National University Chilgok Hospital
      • Daegu, Zuid -Korea, 42601
        • Keimyung University Dongsan Hospital
      • Gyeonggi-do, Zuid -Korea, 10408
        • National Cancer Center
      • Jeollanam-do, Zuid -Korea, 58128
        • Chonnam National University Hwasun Hospital
      • Seoul, Zuid -Korea, 03080
        • Seoul National University Hospital
      • Seoul, Zuid -Korea, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Zuid -Korea, 06351
        • Samsung Medical Center
      • Seoul, Zuid -Korea, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Zuid -Korea, 06591
        • The Catholic University of Korea Seoul St Marys Hospital
      • Seoul, Zuid -Korea, 02841
        • Korea University Anam Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Histologically confirmed initial diagnosis by local pathology (within 90 days of the most recent signed informed consent) of high grade non-muscle invasive bladder cancer (HR-NMIBC) (high-grade Ta, any T1 or carcinoma in-situ [CIS]), in participants who are Bacillus Calmette Guérin (BCG)-naïve
  • BCG-naïve (participants who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before date of randomization are eligible)
  • All visible papillary disease must be fully resected (absent) prior to date of randomization and documented at baseline cystoscopy. Local urine cytology at screening must be negative or atypical (for high-grade urothelial carcinoma [HGUC]) for patients with papillary only disease (without CIS)
  • Eastern Cooperative Oncology Group (ECOG) performance status Grade 0, 1, or 2
  • All adverse events associated with any prior surgery and/or intravesical therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade less than (<) 2 prior to date of randomization
  • Participants must be willing to undergo all study procedures

Exclusion Criteria:

  • Presence or history of histologically confirmed, muscle invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, greater than and equal to [>=] T2)
  • Must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder (that is, urethra, ureter, or renal pelvis). Ta/any T1/CIS of the upper urinary tract (including renal pelvis and ureter) is allowable if treated with complete nephroureterectomy more than 24 months prior to randomization
  • Presence of any bladder or urethral anatomic feature (example, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-200 or administration of intravesical BCG. Participants with tumors involving the prostatic urethra in men will be excluded
  • A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (mL)
  • Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment Group A: TAR-200 + Cetrelimab

Participants will receive intravesical TAR-200 once every 3 weeks (Q3W) and cetrelimab.

Cetrelimab will be administered.

Andere namen:
  • JNJ-63723283

TAR-200 will be administered intravesically.

Andere namen:
  • JNJ-17000139
Actieve vergelijker: Treatment Group B: Bacillus Calmette-Guerin (BCG) Vesiculture

Participants will receive intravesical BCG once every week for 6 weeks (induction) and then followed by once every week for 3 weeks starting at Weeks 12, 24, 48, 72, and 96 (maintenance).

BCG will be administered intravesically.

Experimenteel: Treatment Group C: TAR-200 Alone

Participants will receive intravesical TAR-200 alone once Q3W.

TAR-200 will be administered intravesically.

Andere namen:
  • JNJ-17000139

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Event-free Survival (EFS)
Tijdsspanne: Up to 5 years 2 months

EFS is defined as the time from randomization to either the time of the first recurrence of high-risk disease, progression, or death due to any cause, whichever occurs first. For participants with carcinoma In-situ (CIS), persistent disease at 6 months (Week 24) is also considered an EFS event. Progression is defined as: an increase of stage from Ta to T1 or from CIS to T1 or progression to muscle invasive bladder cancer (MIBC) (T greater than or equal to [>=] 2) or to lymph node (N+) or to distant disease (M+), whichever occurs first.

Up to 5 years 2 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall Complete Response (CR) Rate
Tijdsspanne: Up to 5 years 2 months

Overall CR will be measured by determining the percentage of participants with CIS who have no presence of high-risk disease at 6 months.

Up to 5 years 2 months
Duration of CR
Tijdsspanne: Up to 5 years 2 months

Duration of CR is defined from the time of first CR achieved to first evidence of recurrence, progression or death due to any cause (whichever occurs first) for participants who achieve a CR.

Up to 5 years 2 months
Recurrence-Free Survival (RFS)
Tijdsspanne: Up to 5 years 2 months

RFS is defined as the time from randomization to the time of the first recurrence of high-risk disease, or death due to any cause, whichever occurs first.

Up to 5 years 2 months
Time to Progression (TTP)
Tijdsspanne: Up to 5 years 2 months

TTP is defined as the time from randomization to the date of first documented evidence of disease progression or death due to disease progression, whichever occurs first.

Up to 5 years 2 months
Overall Survival (OS)
Tijdsspanne: Up to 5 years 2 months

OS is defined as the time from randomization to death, due to any cause.

Up to 5 years 2 months
Cancer Specific Survival (CSS)
Tijdsspanne: Up to 5 years 2 months

CSS is defined as the time from randomization to the date of death due to bladder cancer.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs) by Grades According to Common Terminology Criteria for Adverse Events (CTCAE)
Tijdsspanne: Up to 5 years 2 months

Number of participants with AEs by severity grade as assessed by CTCAE version 5 will be reported. Grade refers to the severity of AE as follows: Grade 1- Mild; Grade 2- Moderate; Grade 3- Severe; Grade 4- Life-threatening; Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Adverse Events (AEs)
Tijdsspanne: Up to 5 years 2 months

Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Laboratory Abnormalities
Tijdsspanne: Up to 5 years 2 months

Number of participants with change from baseline in laboratory abnormalities will be reported. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1- Mild, Grade 2- Moderate, Grade 3- Severe, Grade 4- Life-threatening, and Grade 5- Death related to adverse event.

Up to 5 years 2 months
Number of Participants with Change from Baseline in Vital Signs Abnormalities
Tijdsspanne: Up to 5 years 2 months

Number of participants with change from baseline in vital signs (blood pressure [systolic and diastolic], heart rate, temperature, and weight) abnormalities will be reported.

Up to 5 years 2 months
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of life Questionnaire - Non-muscle Invasive Bladder Cancer EORTC QLQ- NMIBC 24
Tijdsspanne: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the Health-related quality of life (HRQoL) of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the quality of life questionnaire (QLQ-C30) and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months
Time to Symptom Deterioration as Assessed by EORTC-QLQ-NMIBC 24 Scores
Tijdsspanne: Up to 5 years 2 months

EORTC QLQ-NMIBC 24 is a 24-item questionnaire for evaluating the HRQoL of participants with superficial (non-muscle-invasive) bladder cancer. The questionnaire is designed to supplement the QLQ-C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much).

Up to 5 years 2 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

23 maart 2023

Primaire voltooiing (Geschat)

18 september 2029

Studie voltooiing (Geschat)

18 september 2029

Studieregistratiedata

Eerst ingediend

27 januari 2023

Eerst ingediend dat voldeed aan de QC-criteria

27 januari 2023

Eerst geplaatst (Werkelijk)

6 februari 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

25 september 2026

Laatste update ingediend die voldeed aan QC-criteria

24 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • CR109223
  • 2020-004506-64 (EudraCT-nummer)
  • 17000139BLC3002 (Andere identificatie: Janssen Research & Development, LLC)
  • 2023-507187-39-00 (Register-ID: EUCT number)
  • 2023 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren